TRIAL DESIGN

The DAP-CORONA RCT is a phase III randomized, triple-blind, placebo-controlled multicentre study on the efficacy and safety of Dapsone in adult patients who have been presenting with symptoms, have been diagnosed with COVID-19 infection and are at high risk of developing complications and requiring hospitalization. Approximately 3 000 individuals who meet the eligibility criteria of this trial will be selected to receive either Dapsone, a generic drug, or placebo tablets for 21 days on a random basis.

Eligible participants will receive the trial medication delivered straight to their doorsteps. During the trial, they will be directly but remotely monitored and supported through the DAP-CORONA VirtualCare platform.

ENROLLMENT STARTED ON NOVEMBER 22, 2021.

SITES ENROLLING: WASHINGTON STATE AND NORTH CAROLINA, USA

ELIGIBILITY

If you answer YES to all of the points below, you are invited to contact the DAP-CORONA trial team to find out if you are eligible.

 

Please call study toll free line: 1-866-DAPC-RCT (1-866-327-2728)
or
TextDAPC‘ to 1-833-4-SMS-DAP (1-833-476-7327)

You are 40 years of age or over.

You are presenting symptoms of COVID-19 in the last four days.

You have tested positive for COVID-19 or have submitted a test sample and waiting for the result or considering taking the COVID-19 test

 

Our study sites are located in:

CANADA

Montreal, Quebec

Toronto, Ontario

USA

High Point, North Carolina

Philadelphia, Pennsylvania

Phoenix, Arizona

Pittsburgh, Pennsylvania

Spokane, Washington State